Trial register facet
Trial records reported in 2023
55 records with a recorded report or completion year of 2023.
Showing 0 records on this page
Records
55 documents · page 1 of 3
Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.
| Record | Compound | Phase | Status | Design | Randomised | Year | Certainty |
|---|---|---|---|---|---|---|---|
| CAGRI-SEMA-PH2-T2D | CagriSema (cagrilintide with semaglutide) | Phase 2 | Reported | Randomised, double-blind, active-controlled | 92 | 2023 | Low |
| CAGRI-SEMA-PH2-T2D-BODY-COMPprogramme record | CagriSema (cagrilintide with semaglutide) | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| CAGRI-SEMA-PH2-T2D-QOLprogramme record | CagriSema (cagrilintide with semaglutide) | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| CAGRI-SEMA-PH2-T2D-REGIONAL-CNprogramme record | CagriSema (cagrilintide with semaglutide) | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| CAGRI-SEMA-PH2-T2D-REGIONAL-JPprogramme record | CagriSema (cagrilintide with semaglutide) | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| DANU-PH2B-OBESITY | Danuglipron | Phase 2b | Programme discontinued | Randomised, double-blind, placebo-controlled | 605 | 2023 | Not rated |
| DANU-PH2B-OBESITY-QOLprogramme record | Danuglipron | Phase 2b | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| DANU-PH2B-OBESITY-REGIONAL-CNprogramme record | Danuglipron | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| DANU-PH2B-OBESITY-REGIONAL-JPprogramme record | Danuglipron | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| DANU-PH2B-T2D | Danuglipron | Phase 2b | Programme discontinued | Randomised, double-blind, placebo-controlled | 411 | 2023 | Not rated |
| DANU-PH2B-T2D-BODY-COMPprogramme record | Danuglipron | Phase 2b | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| DANU-PH2B-T2D-REGIONAL-CNprogramme record | Danuglipron | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| DANU-PH2B-T2D-REGIONAL-JPprogramme record | Danuglipron | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| MAZ-PH2-OBESITY | Mazdutide | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | 248 | 2023 | Moderate |
| MAZ-PH2-OBESITY-BODY-COMPprogramme record | Mazdutide | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| MAZ-PH2-OBESITY-QOLprogramme record | Mazdutide | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| MAZ-PH2-OBESITY-REGIONAL-CNprogramme record | Mazdutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| MAZ-PH2-OBESITY-REGIONAL-JPprogramme record | Mazdutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| OASIS-1 | Semaglutide, oral | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 667 | 2023 | Moderate |
| OASIS-1-ADHERENCEprogramme record | Semaglutide, oral | Phase 3 | Reported | Observational | — | 2023 | Very low |
| OASIS-1-BIOMARKERprogramme record | Semaglutide, oral | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| OASIS-1-OLEprogramme record | Semaglutide, oral | Phase 3 | Reported | Single-arm open-label | — | 2023 | Very low |
| ORFO-PH2-OBESITY | Orforglipron | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | 272 | 2023 | Moderate |
| ORFO-PH2-OBESITY-QOLprogramme record | Orforglipron | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
page 1 of 3